(NASDAQ: ADTX) Aditxt's forecast annual revenue growth rate of 25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Aditxt's revenue in 2024 is $645,176.On average, 1 Wall Street analysts forecast ADTX's revenue for 2024 to be $1,665,214, with the lowest ADTX revenue forecast at $1,665,214, and the highest ADTX revenue forecast at $1,665,214. On average, 1 Wall Street analysts forecast ADTX's revenue for 2025 to be $1,998,257, with the lowest ADTX revenue forecast at $1,998,257, and the highest ADTX revenue forecast at $1,998,257.
In 2026, ADTX is forecast to generate $2,098,170 in revenue, with the lowest revenue forecast at $2,098,170 and the highest revenue forecast at $2,098,170.